RARA and myelodysplastic syndrome: The high prevalence of ARID1A mutations in ZBTB16‐RARA+AML may extend the applicability of APR‐246 treatment, which also targets TP53‐mutations, and has shown efficacy in TP53 mutated cancers,36, 37 including MDS and AML.38, 39